GlaxoSmithKline has signed an agreement with Vir Biotechnology to expand their Covid-19 collaboration to advance new therapeutics for influenza and other respiratory viruses. The company stated that the
The post GlaxoSmithKline and Vir Biotechnology to expand Covid-19 partnership appeared first on Pharmaceutical Business review.
This is not a CAPTIS article. Originally, it was published here.